| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 278 | 2026 | 374 | 63.690 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 119 | 2026 | 466 | 21.680 |
Why?
|
| Antibodies, Monoclonal | 89 | 2026 | 875 | 16.960 |
Why?
|
| Dexamethasone | 74 | 2026 | 214 | 9.790 |
Why?
|
| Antineoplastic Agents | 38 | 2026 | 644 | 9.110 |
Why?
|
| Immunotherapy, Adoptive | 35 | 2026 | 105 | 7.270 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 38 | 2024 | 355 | 6.150 |
Why?
|
| Antibodies, Bispecific | 18 | 2026 | 33 | 5.310 |
Why?
|
| Neoplasm Recurrence, Local | 46 | 2025 | 377 | 4.980 |
Why?
|
| Antineoplastic Agents, Immunological | 15 | 2025 | 50 | 4.960 |
Why?
|
| B-Cell Maturation Antigen | 20 | 2026 | 22 | 4.630 |
Why?
|
| Neoplasm, Residual | 22 | 2026 | 53 | 4.550 |
Why?
|
| Bortezomib | 34 | 2026 | 60 | 4.500 |
Why?
|
| Humans | 307 | 2026 | 65646 | 3.790 |
Why?
|
| Antibodies, Monoclonal, Humanized | 21 | 2026 | 253 | 3.770 |
Why?
|
| Thalidomide | 21 | 2024 | 33 | 3.330 |
Why?
|
| Aged | 133 | 2026 | 15089 | 3.270 |
Why?
|
| Treatment Outcome | 67 | 2026 | 5820 | 2.920 |
Why?
|
| Middle Aged | 123 | 2026 | 18439 | 2.650 |
Why?
|
| Male | 142 | 2026 | 31295 | 2.540 |
Why?
|
| Female | 144 | 2026 | 34309 | 2.460 |
Why?
|
| Transplantation, Autologous | 32 | 2024 | 128 | 2.440 |
Why?
|
| Oligopeptides | 18 | 2025 | 135 | 2.290 |
Why?
|
| Drug Resistance, Neoplasm | 28 | 2026 | 218 | 2.230 |
Why?
|
| Recurrence | 30 | 2026 | 664 | 2.200 |
Why?
|
| Hematologic Neoplasms | 5 | 2025 | 45 | 2.110 |
Why?
|
| Aged, 80 and over | 57 | 2026 | 5656 | 2.050 |
Why?
|
| Adult | 87 | 2026 | 17511 | 2.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2023 | 142 | 1.920 |
Why?
|
| Prognosis | 38 | 2026 | 1791 | 1.890 |
Why?
|
| Biomarkers, Tumor | 16 | 2025 | 526 | 1.710 |
Why?
|
| Genomics | 9 | 2026 | 386 | 1.640 |
Why?
|
| Plasma Cells | 8 | 2022 | 52 | 1.480 |
Why?
|
| T-Lymphocytes | 9 | 2026 | 1010 | 1.460 |
Why?
|
| Injections, Subcutaneous | 11 | 2025 | 70 | 1.450 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 50 | 1.440 |
Why?
|
| Chromosome Aberrations | 8 | 2025 | 70 | 1.310 |
Why?
|
| Melphalan | 9 | 2024 | 23 | 1.270 |
Why?
|
| ADP-ribosyl Cyclase 1 | 6 | 2023 | 26 | 1.260 |
Why?
|
| Clinical Trials as Topic | 10 | 2023 | 462 | 1.220 |
Why?
|
| Quality of Life | 11 | 2026 | 1265 | 1.210 |
Why?
|
| Salvage Therapy | 9 | 2023 | 75 | 1.210 |
Why?
|
| Plasmacytoma | 6 | 2026 | 12 | 1.180 |
Why?
|
| Practice Guidelines as Topic | 8 | 2026 | 741 | 1.180 |
Why?
|
| Administration, Intravenous | 8 | 2022 | 78 | 1.170 |
Why?
|
| Retrospective Studies | 35 | 2026 | 6948 | 1.130 |
Why?
|
| Immunologic Factors | 7 | 2022 | 108 | 1.100 |
Why?
|
| Survival Rate | 18 | 2025 | 847 | 1.040 |
Why?
|
| Flow Cytometry | 5 | 2022 | 664 | 1.020 |
Why?
|
| Smoldering Multiple Myeloma | 6 | 2025 | 6 | 0.990 |
Why?
|
| Cell- and Tissue-Based Therapy | 6 | 2023 | 42 | 0.990 |
Why?
|
| Myeloma Proteins | 7 | 2021 | 7 | 0.970 |
Why?
|
| Immunization, Secondary | 1 | 2026 | 52 | 0.940 |
Why?
|
| Immunoglobulin Light Chains | 4 | 2021 | 16 | 0.930 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2023 | 8 | 0.920 |
Why?
|
| Immunotherapy | 6 | 2026 | 274 | 0.920 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2011 | 63 | 0.910 |
Why?
|
| Proteasome Inhibitors | 11 | 2026 | 32 | 0.890 |
Why?
|
| Physicians | 4 | 2023 | 486 | 0.880 |
Why?
|
| Chromosomes, Human, Pair 1 | 4 | 2025 | 23 | 0.860 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 231 | 0.860 |
Why?
|
| Membrane Glycoproteins | 5 | 2020 | 667 | 0.840 |
Why?
|
| Neoplasm Staging | 10 | 2026 | 552 | 0.820 |
Why?
|
| Translocation, Genetic | 7 | 2026 | 74 | 0.810 |
Why?
|
| Maintenance Chemotherapy | 5 | 2025 | 17 | 0.800 |
Why?
|
| Follow-Up Studies | 18 | 2026 | 2496 | 0.780 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2025 | 161 | 0.770 |
Why?
|
| Disease Progression | 17 | 2026 | 1227 | 0.760 |
Why?
|
| CD3 Complex | 1 | 2022 | 63 | 0.730 |
Why?
|
| Disease-Free Survival | 15 | 2022 | 245 | 0.710 |
Why?
|
| Injection Site Reaction | 2 | 2021 | 4 | 0.710 |
Why?
|
| Health Status Disparities | 1 | 2023 | 147 | 0.700 |
Why?
|
| Sulfides | 2 | 2020 | 22 | 0.670 |
Why?
|
| Acetates | 2 | 2020 | 30 | 0.670 |
Why?
|
| Quinolines | 2 | 2020 | 47 | 0.660 |
Why?
|
| Cyclopropanes | 2 | 2020 | 56 | 0.660 |
Why?
|
| Immunoconjugates | 2 | 2024 | 95 | 0.650 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2021 | 91 | 0.650 |
Why?
|
| Transplantation Conditioning | 5 | 2019 | 101 | 0.650 |
Why?
|
| Cytochrome P-450 CYP1A2 Inducers | 1 | 2020 | 1 | 0.640 |
Why?
|
| Amyloidosis | 3 | 2016 | 70 | 0.640 |
Why?
|
| Risk Assessment | 7 | 2025 | 2113 | 0.640 |
Why?
|
| Models, Statistical | 1 | 2022 | 309 | 0.630 |
Why?
|
| Thromboembolism | 1 | 2020 | 74 | 0.630 |
Why?
|
| Drug Administration Schedule | 8 | 2021 | 296 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2024 | 710 | 0.590 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 410 | 0.590 |
Why?
|
| Immunophenotyping | 2 | 2018 | 194 | 0.590 |
Why?
|
| Karnofsky Performance Status | 1 | 2019 | 13 | 0.580 |
Why?
|
| Induction Chemotherapy | 7 | 2023 | 44 | 0.580 |
Why?
|
| Bone Neoplasms | 2 | 2026 | 124 | 0.570 |
Why?
|
| Incidence | 9 | 2026 | 1432 | 0.570 |
Why?
|
| Immunomodulation | 1 | 2018 | 30 | 0.570 |
Why?
|
| Prospective Studies | 14 | 2026 | 3329 | 0.570 |
Why?
|
| Frailty | 3 | 2026 | 132 | 0.550 |
Why?
|
| Gene Expression Profiling | 8 | 2025 | 797 | 0.550 |
Why?
|
| Dental Prophylaxis | 1 | 2018 | 1 | 0.540 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 4 | 2025 | 35 | 0.540 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2021 | 420 | 0.540 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2025 | 49 | 0.530 |
Why?
|
| Cell Proliferation | 3 | 2026 | 1044 | 0.520 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 102 | 0.520 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2017 | 6 | 0.510 |
Why?
|
| Survival Analysis | 7 | 2020 | 579 | 0.510 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2016 | 39 | 0.510 |
Why?
|
| Catheterization, Central Venous | 1 | 2018 | 84 | 0.510 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2025 | 858 | 0.510 |
Why?
|
| Lymphoma, B-Cell | 3 | 2025 | 63 | 0.500 |
Why?
|
| Bacteremia | 1 | 2018 | 91 | 0.500 |
Why?
|
| Cancer Survivors | 1 | 2018 | 130 | 0.490 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 33 | 0.480 |
Why?
|
| Ambulatory Care | 1 | 2019 | 318 | 0.480 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 297 | 0.480 |
Why?
|
| Infusions, Intravenous | 4 | 2021 | 193 | 0.480 |
Why?
|
| Disease Management | 6 | 2021 | 235 | 0.480 |
Why?
|
| Blood Transfusion | 1 | 2017 | 167 | 0.480 |
Why?
|
| United States | 12 | 2023 | 8166 | 0.480 |
Why?
|
| Health Status | 1 | 2019 | 448 | 0.470 |
Why?
|
| Bone Marrow | 7 | 2023 | 176 | 0.470 |
Why?
|
| Skin Diseases, Infectious | 1 | 2016 | 12 | 0.470 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 15 | 0.470 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 129 | 0.470 |
Why?
|
| Tumor Microenvironment | 6 | 2025 | 183 | 0.460 |
Why?
|
| Standard of Care | 3 | 2026 | 29 | 0.430 |
Why?
|
| Boron Compounds | 3 | 2024 | 22 | 0.430 |
Why?
|
| Proportional Hazards Models | 8 | 2023 | 746 | 0.420 |
Why?
|
| Glycine | 3 | 2024 | 48 | 0.420 |
Why?
|
| Risk Factors | 13 | 2026 | 5466 | 0.420 |
Why?
|
| Hepatitis C | 1 | 2016 | 144 | 0.410 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 372 | 0.410 |
Why?
|
| Biomarkers | 7 | 2022 | 1487 | 0.410 |
Why?
|
| Remission Induction | 6 | 2025 | 149 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 588 | 0.410 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 220 | 0.400 |
Why?
|
| Thrombocytopenia | 2 | 2025 | 59 | 0.400 |
Why?
|
| Neoplasms | 2 | 2018 | 1376 | 0.400 |
Why?
|
| Serum Amyloid A Protein | 1 | 2013 | 7 | 0.390 |
Why?
|
| Cost-Benefit Analysis | 3 | 2026 | 318 | 0.380 |
Why?
|
| Young Adult | 12 | 2025 | 4855 | 0.380 |
Why?
|
| Leukemia | 1 | 2013 | 62 | 0.380 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2024 | 139 | 0.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2023 | 27 | 0.370 |
Why?
|
| Neoplasms, Plasma Cell | 2 | 2023 | 3 | 0.360 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2012 | 32 | 0.360 |
Why?
|
| Precancerous Conditions | 3 | 2025 | 74 | 0.360 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 93 | 0.360 |
Why?
|
| Hemophilia A | 1 | 2011 | 57 | 0.350 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2011 | 34 | 0.350 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2020 | 161 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 58 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2026 | 735 | 0.340 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2021 | 89 | 0.330 |
Why?
|
| Clinical Decision-Making | 3 | 2025 | 170 | 0.330 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2026 | 23 | 0.330 |
Why?
|
| Adolescent | 10 | 2026 | 6350 | 0.330 |
Why?
|
| Benzodioxoles | 1 | 2010 | 12 | 0.330 |
Why?
|
| Feasibility Studies | 2 | 2026 | 593 | 0.320 |
Why?
|
| Purines | 1 | 2010 | 43 | 0.320 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2023 | 15 | 0.320 |
Why?
|
| Lymphoma, T-Cell | 2 | 2025 | 23 | 0.320 |
Why?
|
| Cytogenetic Analysis | 5 | 2022 | 26 | 0.320 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 2 | 2021 | 6 | 0.320 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2022 | 15 | 0.320 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2020 | 63 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2018 | 2262 | 0.310 |
Why?
|
| DNA Copy Number Variations | 3 | 2024 | 73 | 0.310 |
Why?
|
| Stem Cell Transplantation | 3 | 2023 | 79 | 0.300 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2025 | 128 | 0.300 |
Why?
|
| Europe | 2 | 2020 | 199 | 0.300 |
Why?
|
| Databases, Factual | 5 | 2026 | 888 | 0.300 |
Why?
|
| Benzoquinones | 1 | 2009 | 14 | 0.300 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 308 | 0.300 |
Why?
|
| Lactams, Macrocyclic | 1 | 2009 | 31 | 0.290 |
Why?
|
| Diet, Vegetarian | 2 | 2026 | 5 | 0.290 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 409 | 0.280 |
Why?
|
| Japan | 2 | 2026 | 67 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 809 | 0.280 |
Why?
|
| Boronic Acids | 3 | 2013 | 28 | 0.270 |
Why?
|
| Neutropenia | 3 | 2023 | 68 | 0.270 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2026 | 281 | 0.270 |
Why?
|
| Pyrazines | 3 | 2013 | 35 | 0.270 |
Why?
|
| Consensus | 3 | 2024 | 177 | 0.270 |
Why?
|
| Chromosome Deletion | 2 | 2020 | 42 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2025 | 205 | 0.260 |
Why?
|
| Bone Marrow Cells | 4 | 2022 | 237 | 0.260 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2730 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2020 | 222 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2026 | 642 | 0.250 |
Why?
|
| Myeloablative Agonists | 3 | 2015 | 12 | 0.240 |
Why?
|
| Surveys and Questionnaires | 3 | 2026 | 2789 | 0.240 |
Why?
|
| Cyclin D1 | 1 | 2026 | 17 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2026 | 18 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2026 | 11 | 0.240 |
Why?
|
| Diarrhea | 2 | 2024 | 73 | 0.240 |
Why?
|
| Mutation | 5 | 2026 | 2670 | 0.240 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2026 | 22 | 0.240 |
Why?
|
| Health Care Costs | 2 | 2025 | 224 | 0.230 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2026 | 39 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2024 | 182 | 0.230 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 25 | 0.230 |
Why?
|
| Immunity, Humoral | 1 | 2025 | 40 | 0.220 |
Why?
|
| Dietary Fiber | 1 | 2026 | 80 | 0.220 |
Why?
|
| Mutagenesis | 1 | 2025 | 133 | 0.220 |
Why?
|
| Chemoradiotherapy | 1 | 2025 | 75 | 0.220 |
Why?
|
| Sulfonamides | 1 | 2026 | 133 | 0.220 |
Why?
|
| Chromatography, Liquid | 2 | 2021 | 119 | 0.210 |
Why?
|
| Whole Genome Sequencing | 4 | 2025 | 89 | 0.210 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 286 | 0.200 |
Why?
|
| DNA Damage | 1 | 2026 | 298 | 0.200 |
Why?
|
| Models, Theoretical | 1 | 2025 | 274 | 0.200 |
Why?
|
| Animals | 11 | 2026 | 21465 | 0.200 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2016 | 134 | 0.200 |
Why?
|
| Rituximab | 2 | 2015 | 89 | 0.200 |
Why?
|
| CD47 Antigen | 1 | 2023 | 6 | 0.190 |
Why?
|
| Meta-Analysis as Topic | 1 | 2023 | 78 | 0.190 |
Why?
|
| Gene Deletion | 2 | 2024 | 312 | 0.190 |
Why?
|
| Heterocyclic Compounds | 1 | 2022 | 12 | 0.190 |
Why?
|
| Spain | 2 | 2020 | 32 | 0.190 |
Why?
|
| Gene Dosage | 2 | 2021 | 72 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 314 | 0.190 |
Why?
|
| Sex Factors | 2 | 2023 | 995 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 113 | 0.180 |
Why?
|
| Canada | 2 | 2020 | 157 | 0.180 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 404 | 0.180 |
Why?
|
| Workflow | 1 | 2022 | 77 | 0.180 |
Why?
|
| Biological Therapy | 1 | 2022 | 16 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 1662 | 0.180 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2021 | 2 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 679 | 0.170 |
Why?
|
| Software | 1 | 2025 | 401 | 0.170 |
Why?
|
| Electrocardiography | 1 | 2024 | 555 | 0.170 |
Why?
|
| Nutritional Status | 1 | 2022 | 101 | 0.170 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 22 | 0.170 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 1573 | 0.170 |
Why?
|
| Time Factors | 5 | 2020 | 3777 | 0.170 |
Why?
|
| Population Surveillance | 2 | 2020 | 210 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 216 | 0.170 |
Why?
|
| Retreatment | 2 | 2019 | 43 | 0.170 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 102 | 0.160 |
Why?
|
| Genetic Loci | 1 | 2021 | 117 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 193 | 0.160 |
Why?
|
| Administration, Cutaneous | 1 | 2020 | 31 | 0.160 |
Why?
|
| Patient Dropouts | 1 | 2020 | 51 | 0.160 |
Why?
|
| Denmark | 1 | 2020 | 19 | 0.160 |
Why?
|
| Netherlands | 1 | 2020 | 26 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2021 | 70 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 442 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 169 | 0.160 |
Why?
|
| Sweden | 1 | 2020 | 65 | 0.160 |
Why?
|
| Influenza, Human | 1 | 2022 | 210 | 0.160 |
Why?
|
| Hemoglobins | 2 | 2018 | 136 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 603 | 0.150 |
Why?
|
| Drug Compounding | 1 | 2020 | 80 | 0.150 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 296 | 0.150 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 273 | 0.150 |
Why?
|
| Prednisone | 1 | 2019 | 83 | 0.150 |
Why?
|
| Thrombopoietin | 1 | 2019 | 11 | 0.150 |
Why?
|
| Apoptosis | 3 | 2023 | 1100 | 0.150 |
Why?
|
| Paraproteinemias | 1 | 2019 | 16 | 0.150 |
Why?
|
| Infusion Pumps | 1 | 2020 | 32 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 472 | 0.150 |
Why?
|
| Diphenhydramine | 1 | 2019 | 9 | 0.150 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 17 | 0.150 |
Why?
|
| Premedication | 1 | 2019 | 20 | 0.150 |
Why?
|
| Risk | 5 | 2021 | 374 | 0.150 |
Why?
|
| Transplantation, Haploidentical | 1 | 2018 | 3 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2019 | 39 | 0.150 |
Why?
|
| Cystitis | 1 | 2018 | 10 | 0.140 |
Why?
|
| Stem Cells | 1 | 2021 | 276 | 0.140 |
Why?
|
| Receptors, KIR | 1 | 2018 | 4 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 154 | 0.140 |
Why?
|
| Ibuprofen | 1 | 2018 | 17 | 0.140 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2018 | 9 | 0.140 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2018 | 5 | 0.140 |
Why?
|
| Thoracic Vertebrae | 1 | 2018 | 35 | 0.140 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 72 | 0.140 |
Why?
|
| Cell Count | 1 | 2018 | 128 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 555 | 0.140 |
Why?
|
| Cytogenetics | 2 | 2016 | 9 | 0.140 |
Why?
|
| Acetaminophen | 1 | 2019 | 53 | 0.140 |
Why?
|
| Models, Biological | 2 | 2020 | 1193 | 0.140 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 29 | 0.140 |
Why?
|
| Back Pain | 1 | 2018 | 49 | 0.140 |
Why?
|
| Periodontal Index | 1 | 2018 | 4 | 0.140 |
Why?
|
| Drugs, Investigational | 1 | 2018 | 12 | 0.140 |
Why?
|
| Pandemics | 1 | 2023 | 691 | 0.140 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2018 | 50 | 0.130 |
Why?
|
| Receptors, IgG | 1 | 2018 | 41 | 0.130 |
Why?
|
| Patient Safety | 1 | 2021 | 281 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 59 | 0.130 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 42 | 0.130 |
Why?
|
| Mice | 6 | 2026 | 11174 | 0.130 |
Why?
|
| Bone and Bones | 2 | 2016 | 152 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2019 | 190 | 0.130 |
Why?
|
| Comorbidity | 1 | 2020 | 1120 | 0.130 |
Why?
|
| Phagocytosis | 1 | 2018 | 257 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 744 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 102 | 0.130 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 565 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2018 | 286 | 0.120 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 178 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2018 | 757 | 0.120 |
Why?
|
| Gene Expression | 1 | 2020 | 854 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2019 | 2639 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 47 | 0.120 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 8 | 0.120 |
Why?
|
| Janus Kinase 1 | 1 | 2016 | 17 | 0.120 |
Why?
|
| Pneumonia | 1 | 2019 | 295 | 0.120 |
Why?
|
| Schnitzler Syndrome | 1 | 2016 | 1 | 0.120 |
Why?
|
| POEMS Syndrome | 1 | 2016 | 2 | 0.120 |
Why?
|
| Cryoglobulinemia | 1 | 2016 | 3 | 0.120 |
Why?
|
| Scleromyxedema | 1 | 2016 | 2 | 0.120 |
Why?
|
| Xanthomatosis | 1 | 2016 | 8 | 0.120 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 196 | 0.120 |
Why?
|
| Phenotype | 1 | 2020 | 1235 | 0.120 |
Why?
|
| Osteoclasts | 2 | 2013 | 53 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 70 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2012 | 6 | 0.120 |
Why?
|
| ErbB Receptors | 1 | 2016 | 128 | 0.110 |
Why?
|
| Lymphoma, Follicular | 1 | 2015 | 18 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 1 | 2015 | 140 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2026 | 900 | 0.110 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2025 | 47 | 0.110 |
Why?
|
| Bone Remodeling | 1 | 2015 | 25 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 106 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2015 | 129 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 38 | 0.110 |
Why?
|
| Medicare | 1 | 2019 | 629 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 68 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 24 | 0.100 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 53 | 0.100 |
Why?
|
| Unfolded Protein Response | 2 | 2013 | 62 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 1 | 2013 | 29 | 0.100 |
Why?
|
| Administration, Metronomic | 1 | 2013 | 1 | 0.100 |
Why?
|
| Radiography | 2 | 2012 | 558 | 0.100 |
Why?
|
| Cell Separation | 1 | 2013 | 147 | 0.100 |
Why?
|
| Transplantation, Homologous | 3 | 2022 | 250 | 0.100 |
Why?
|
| Castleman Disease | 1 | 2013 | 4 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 83 | 0.100 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 5 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 100 | 0.100 |
Why?
|
| Osteolysis | 1 | 2013 | 19 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2013 | 25 | 0.100 |
Why?
|
| Piperidines | 3 | 2020 | 73 | 0.090 |
Why?
|
| Mice, SCID | 4 | 2016 | 518 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2016 | 3164 | 0.090 |
Why?
|
| Cell Cycle | 2 | 2013 | 398 | 0.090 |
Why?
|
| Myelolipoma | 1 | 2012 | 1 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 94 | 0.090 |
Why?
|
| Genome, Human | 2 | 2025 | 238 | 0.090 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2012 | 28 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 1288 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1567 | 0.090 |
Why?
|
| Hemarthrosis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Factor VIII | 1 | 2011 | 32 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 41 | 0.090 |
Why?
|
| Blood Coagulation Factors | 1 | 2011 | 16 | 0.090 |
Why?
|
| Pericardial Effusion | 1 | 2011 | 22 | 0.090 |
Why?
|
| Hydrazines | 2 | 2022 | 9 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2026 | 1144 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 408 | 0.080 |
Why?
|
| Acute Disease | 1 | 2013 | 663 | 0.080 |
Why?
|
| Vaccination | 2 | 2025 | 388 | 0.080 |
Why?
|
| Triazoles | 2 | 2022 | 63 | 0.080 |
Why?
|
| Cell Movement | 1 | 2013 | 484 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 185 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 95 | 0.080 |
Why?
|
| Body Weight | 2 | 2023 | 377 | 0.080 |
Why?
|
| G1 Phase | 1 | 2010 | 58 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 931 | 0.080 |
Why?
|
| Heart Failure | 1 | 2018 | 965 | 0.080 |
Why?
|
| S Phase | 1 | 2010 | 79 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 463 | 0.080 |
Why?
|
| Pain | 2 | 2023 | 400 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 161 | 0.080 |
Why?
|
| Diet | 2 | 2024 | 536 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2021 | 84 | 0.080 |
Why?
|
| Fatigue | 2 | 2022 | 114 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 2 | 2020 | 48 | 0.080 |
Why?
|
| International Agencies | 2 | 2019 | 7 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 44 | 0.070 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1389 | 0.070 |
Why?
|
| Adenine | 2 | 2020 | 48 | 0.070 |
Why?
|
| Cytokines | 1 | 2013 | 964 | 0.070 |
Why?
|
| Nausea | 1 | 2009 | 111 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2020 | 88 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2020 | 144 | 0.070 |
Why?
|
| Vomiting | 1 | 2009 | 139 | 0.070 |
Why?
|
| Algorithms | 2 | 2025 | 1052 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2021 | 98 | 0.060 |
Why?
|
| Cisplatin | 2 | 2021 | 145 | 0.060 |
Why?
|
| Lymphocytosis | 1 | 2026 | 4 | 0.060 |
Why?
|
| Thymus Hyperplasia | 1 | 2006 | 2 | 0.060 |
Why?
|
| Lymphopenia | 1 | 2026 | 35 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 92 | 0.060 |
Why?
|
| Child | 2 | 2026 | 4634 | 0.060 |
Why?
|
| Models, Economic | 1 | 2026 | 42 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2026 | 47 | 0.060 |
Why?
|
| HIV Infections | 1 | 2013 | 958 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2026 | 115 | 0.060 |
Why?
|
| Asia | 1 | 2025 | 25 | 0.060 |
Why?
|
| Trisomy | 1 | 2025 | 22 | 0.060 |
Why?
|
| Brain | 1 | 2013 | 1625 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2025 | 122 | 0.050 |
Why?
|
| Lentivirus | 1 | 2025 | 64 | 0.050 |
Why?
|
| Biological Products | 1 | 2026 | 93 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2024 | 78 | 0.050 |
Why?
|
| Sweetening Agents | 1 | 2024 | 20 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2026 | 279 | 0.050 |
Why?
|
| Protein Interaction Maps | 1 | 2023 | 35 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 37 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 149 | 0.050 |
Why?
|
| Germinal Center | 1 | 2023 | 40 | 0.050 |
Why?
|
| Social Support | 1 | 2026 | 394 | 0.050 |
Why?
|
| Proteinuria | 1 | 2023 | 41 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 16 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2023 | 74 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2023 | 203 | 0.050 |
Why?
|
| Registries | 1 | 2026 | 934 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 277 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 167 | 0.040 |
Why?
|
| Single-Chain Antibodies | 1 | 2021 | 5 | 0.040 |
Why?
|
| Diterpenes | 1 | 2021 | 13 | 0.040 |
Why?
|
| Filgrastim | 1 | 2021 | 8 | 0.040 |
Why?
|
| Etoposide | 1 | 2021 | 34 | 0.040 |
Why?
|
| RNA Interference | 2 | 2016 | 647 | 0.040 |
Why?
|
| Taiwan | 1 | 2021 | 14 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 898 | 0.040 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2020 | 10 | 0.040 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2020 | 10 | 0.040 |
Why?
|
| Infant | 1 | 2026 | 1711 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2013 | 376 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 38 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2020 | 38 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 54 | 0.040 |
Why?
|
| Benchmarking | 1 | 2021 | 137 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cost Savings | 1 | 2021 | 60 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 160 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2026 | 2076 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 35 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 218 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2020 | 52 | 0.040 |
Why?
|
| Kidney | 1 | 2023 | 458 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 294 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 209 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 328 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 439 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1453 | 0.040 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2019 | 11 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2020 | 344 | 0.040 |
Why?
|
| Jehovah's Witnesses | 1 | 2019 | 19 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 316 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 40 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 181 | 0.040 |
Why?
|
| Basophils | 1 | 2018 | 15 | 0.040 |
Why?
|
| Granzymes | 1 | 2018 | 22 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 505 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2018 | 111 | 0.040 |
Why?
|
| Drug Approval | 1 | 2018 | 28 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2026 | 2327 | 0.030 |
Why?
|
| Myocarditis | 1 | 2019 | 68 | 0.030 |
Why?
|
| Autografts | 1 | 2017 | 9 | 0.030 |
Why?
|
| Hematology | 1 | 2017 | 11 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 47 | 0.030 |
Why?
|
| Education | 1 | 2017 | 66 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 1233 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 199 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 28 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 990 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 19 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2016 | 66 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 590 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 884 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 221 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2016 | 96 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 1715 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2016 | 143 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 203 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 101 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1403 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 400 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 542 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 611 | 0.030 |
Why?
|
| Karyotype | 1 | 2014 | 18 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 187 | 0.030 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2014 | 12 | 0.030 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2013 | 17 | 0.030 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2013 | 35 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 40 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 167 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2013 | 25 | 0.020 |
Why?
|
| Acrylamides | 1 | 2013 | 13 | 0.020 |
Why?
|
| Nicotinamide Mononucleotide | 1 | 2013 | 2 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2013 | 104 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 31 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 27 | 0.020 |
Why?
|
| Niacinamide | 1 | 2013 | 33 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 18 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 241 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 43 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2013 | 104 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2013 | 27 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 92 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 87 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 82 | 0.020 |
Why?
|
| Amides | 1 | 2013 | 60 | 0.020 |
Why?
|
| NAD | 1 | 2013 | 54 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1592 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 178 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 206 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 426 | 0.020 |
Why?
|
| Rabbits | 1 | 2013 | 342 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 210 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 230 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 588 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 25 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 24 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2013 | 351 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2013 | 435 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 369 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1291 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2193 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2029 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 446 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1226 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2013 | 1559 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 992 | 0.010 |
Why?
|